Evicenter
MarkdownMedical informationP&T meetings
Dersimelagon (MT-7117)

Erythropoietic protoporphyria or X-linked protoporphyria

Manufacturer
LEO Pharma
Last updated
100 sources

Section 3 of 6

Product information and disease description

171 evidence topics · 77 sources

Product description

Phase of product development

European Union submission route and expected registration
Horizon-scan fieldQuoted record
Registration route“Centralised (EMA)”
Submission date“July 2026”
Expected Registration“August 2027”
Orphan drug“Yes”
Regulatory submission in Japan

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Proposed brand name

No evidence found.

Dosage forms and strengths
Commercial tablet strengths

No evidence found.

Average sales price and wholesale acquisition cost
United States wholesale acquisition cost and average sales price

No evidence found.

American hospital formulary service (AHFS), or other drug classification
American Hospital Formulary Service classification and WHO Anatomical Therapeutic Chemical code

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Approved labeling

No evidence found.

Contraindications

No evidence found.

Special populations
Children younger than 12 years

No evidence found.

Drug/Drug, drug/disease interactions
Effects of other drugs on Dersimelagon
Effects of Dersimelagon on other drugs
Dosing and administration
Dosage
Administration
Access and distribution

No evidence found.

Co-prescribed/Concomitant therapies
Effect of Dersimelagon on quality measures

No evidence found.

Product comparison
Summary: products approved or in late-stage development for these disorders

Afamelanotide is the only approved product. It shares dersimelagon's target, the melanocortin 1 receptor, but is given as a 16 mg fixed-dose subcutaneous implant every 2 months by a trained and accredited implanter, is indicated for adults with erythropoietic protoporphyria only, and has no established safety or effectiveness in patients under 18 years. Two investigational products act on protoporphyrin IX rather than on pigmentation. Bitopertin, a glycine transporter 1 inhibitor taken orally, lowers whole-blood metal-free protoporphyrin IX; its application for accelerated approval received a complete response letter in February 2026 after the Food and Drug Administration concluded that the phase 2 trials did not show an association between the change in protoporphyrin IX and sunlight-exposure endpoints, and its phase 3 APOLLO trial is ongoing. PORT-77, an oral ABCG2 inhibitor, reduced plasma protoporphyrin IX in a phase 2a study and entered phase 2b/3 in September 2026. No head-to-head trial, network meta-analysis, or indirect treatment comparison exists across these products, and each program uses a different primary endpoint, so relative efficacy cannot be estimated from the published evidence.

Place of product in therapy

Disease description

Definition and etiology
Epidemiology
Incidence of Erythropoietic protoporphyria or X-linked protoporphyria
Incidence of X-linked protoporphyria

No evidence found.

Prevalence of Erythropoietic protoporphyria or X-linked protoporphyria
Natural history, survival, and mortality
Pathophysiology
Diagnosis
Diagnostic delay
Clinical presentation - signs and symptoms
Cutaneous symptoms: prodromal tingling, burning, and phototoxic pain
Hematologic symptoms: microcytic anemia and iron deficiency
Long-term morbidity
Burden of Erythropoietic protoporphyria or X-linked protoporphyria
Humanistic burden and health-related quality of life
Performance of quality-of-life instruments in this disease
Economic burden and healthcare resource utilization
Monetized indirect costs and productivity loss

No evidence found.

Economic impact of Erythropoietic protoporphyria or X-linked protoporphyria on families
Quantified family out-of-pocket costs and caregiver productivity loss

No evidence found.

Economic impact of diagnostic testing
Testing that guidelines recommend against

“Clinicians should avoid laboratories that measure protoporphyrin only by hematofluorometry, which can lead to falsely normal levels of erythrocyte protoporphyrins, and these results are often incorrectly labeled as “free erythrocyte protoporphyrin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In patients with protoporphyria, plasma porphyrin levels may be normal or increased” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Elevated plasma porphyrins are not diagnostic of EPP and are therefore not recommended as first-line testing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Urinary and fecal porphyrins are typically normal in protoporphyria, and testing is not recommended” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Skin biopsies are not indicated for the diagnosis of protoporphyria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Genetic testing in the absence of biochemical testing is not recommended given the possibility of identifying variants of uncertain significance and the small percentage of patients in whom the genetic variant remains undefined” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Cost of genetic testing and of misdiagnosis

No evidence found.

Approaches to treatment

Current treatment options and standard of care
Sunlight avoidance and photoprotective measures
Guideline recommendation for avoidance, clothing, and tinted sunscreens
Melanocortin 1 receptor agonists
Oral antioxidants and other systemic agents
Phototherapy and sunlight hardening
Management of acute phototoxic reactions
Management of hepatobiliary complications
Course of protoporphyric hepatopathy and monitoring recommendation

“Approximately 1–5% of patients with protoporphyria develop rapid and severe hepatobiliary disease characterized by an acute cholestatic hepatitis with liver failure (often called “EPP hepatic crisis”), or a slowly progressive biliary cirrhosis and end stage liver disease; these more advanced manifestations of liver disease due to protoporphyria are collectively referred to as “protoporphyric hepatopathy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“These patients almost invariably require liver transplantation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Therefore, it is recommended that liver chemistries should be monitored at least yearly in patients with protoporphyria to detect early stages of liver dysfunction starting at the time of diagnosis of protoporphyria ( Figure 4” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend TPE for patients with advanced protoporphyric hepatopathy to decrease plasma porphyrin levels and thereby reduce liver damage in order to bridge patients to liver transplant and/or hematopoietic stem cell transplant (see below” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Recurrent protoporphyric hepatopathy in the transplanted liver has been reported in 65 to 80% of patients in case series from the US, Australia, and Europe, with 43% showing evidence of recurrence by one year post-transplant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Limitations of current therapies
Summary: constraints on the current standard of care

No therapy is approved for patients younger than 18 years, and afamelanotide, the only approved product, is indicated for adults with erythropoietic protoporphyria and not for X-linked protoporphyria. Afamelanotide is a fixed-dose subcutaneous implant administered every 2 months by a trained and accredited implanter at a recognized porphyria center, which limits dose adjustment and restricts the sites able to provide it. In a United States claims analysis of 696 patients with either disorder, 7.6% received any treatment for the condition and 3.9% received afamelanotide, with a median treatment duration of 5.68 months. Clinical practice guidelines recommend against beta-carotene, cysteine, cimetidine, and other systemic agents for prevention of phototoxic symptoms, and identify no effective treatment for an established phototoxic reaction. Sunlight avoidance remains necessary during treatment and is associated with vitamin D deficiency.

Place in treatment, anticipated use, and care setting
Summary: anticipated position of an oral melanocortin 1 receptor agonist

Dersimelagon shares its mechanism with afamelanotide, the only approved therapy, but is taken as a once-daily oral tablet rather than a subcutaneous implant placed every 2 months by an accredited implanter. If approved on the submitted application, it would be the first therapy available to patients aged 12 to 17 years and the first approved specifically for X-linked protoporphyria as well as erythropoietic protoporphyria. The phase 3 INSPIRE population was treatment-naive for dersimelagon and excluded participants receiving other active treatment for either disorder, so no evidence describes use after or alongside afamelanotide. Care would remain specialist-led: clinical practice guidelines recommend annual liver chemistries, an annual complete blood count and iron panel, vitamin D screening, and total body skin examination every 6 months for patients receiving a melanocortin 1 receptor agonist.

Heterogeneity of treatment effect
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy
Summary: outcomes a melanocortin 1 receptor agonist is expected to change

Therapy with a melanocortin 1 receptor agonist is symptomatic. It is expected to increase the time a patient can spend in sunlight before symptoms begin, reduce the number of sunlight-induced pain events, and improve patient-reported global impression and quality of life. It is not expected to lower protoporphyrin concentrations or to alter the risk of protoporphyric hepatopathy, and sunlight protection measures continue during treatment. The regulatory precedent for the approved comparator used hours of direct sunlight exposure without pain as the primary endpoint; the dersimelagon program instead used minutes of daily sunlight exposure before the first prodromal symptom, so effect sizes are not directly comparable between the two products.